壽康集團(00575.HK):極其鼓舞的早泄藥Fortacin™美國市場研究分析
格隆匯7月28日丨壽康集團(00575.HK)公佈,美國領先的全球醫療保健市場研究公司之一MME已剛完成對Fortacin™於美國潛力的詳細市場評估。該問卷涉及70名根據地域代表性挑選的泌尿科醫生及初級診療醫生,包括性健康專家及初級診療醫生。
作為一個羣體,71%的受訪者認為早泄治療有大量未滿足需求,且現有治療方法並非特別成功。當呈列Fortacin™的目標概況時,90%的醫生認為該產品作為一線治療具有價值並深受病人歡迎,彼等肯定會開出處方。
值得鼓舞的是,即使現有治療存在限制,該等醫生平均每月治療21名病人。這將高於批准偉哥前出現的勃起功能障礙病人數量。
與此同時,價格敏感度亦於美國以每月90至150美元的範圍進行測試。即使作為"現金支付",該範圍內的市場推出價格亦獲確認為容易實現。
公司行政總裁Jamie Gibson表示:"數據確認美國境內商業機會的規模。這表明需要經批准處方產品,而Fortacin™應以極具吸引力的價格滿足該等需求。我們預計一旦推出Fortacin™,其可於推出後一至兩年內成為市場領導者。該分析將促進與許可方的持續討論,儘管公司同時承諾通過完成第三期隨機化臨牀試驗計劃及提交新藥申請以增加更多價值。"
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.